Results 91 to 100 of about 7,787 (204)
Proceedings, 2017 Benznidazole and nifurtimox, the currently available drugs for the specific treatment of Chagas disease, show limited effectiveness and high toxicity that prompt the identification of therapeutic alternatives. [...]
Cristina Fonseca-Berzal +9 more
doaj +1 more source
Eflornithine is Safer Than Melarsoprol for the Treatment of Second-Stage Trypanosoma Brucei Gambiense Human African Trypanosomiasis. [PDF]
, 2005 Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects ...
A. Meussen +10 more
core +2 more sources
The pharmacokinetics of nifurtimox in chronic renal failure
European Journal of Clinical Pharmacology, 1992 The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration.
González-Martin, G. +4 more
openaire +3 more sources
Memorias do Instituto Oswaldo Cruz, 1987 Megazol, nifurtimox, benznidazol and allopurinol were investigated, by light and electron µscopy, for their action on T. cruzi. Both the direct effect upon amastigote and trypomastigote forms and the effect upon the interaction of heart muscle cells (HMC)
Solange L. de Castro +1 more
doaj +1 more source
Transport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei [PDF]
, 2015 Drug resistance in pathogenic protozoa is very often caused by changes to the ‘transportome’ of the parasites. In Trypanosoma brucei, several transporters have been implicated in uptake of the main classes of drugs, diamidines and melaminophenyl ...
De Koning, Harry P. +2 more
core +1 more source
Chagas disease: Present status of pathogenic mechanisms and chemotherapy
Biological Research, 2010 There are approximately 7.8 million people in Latin America, including Chile, who suffer from Chagas disease and another 28 million who are at risk of contracting it. Chagas is caused by the flagellate protozoan Trypanosoma cruzi. It is a chronic disease,
Juan Diego Maya +5 more
doaj
Memorias do Instituto Oswaldo Cruz, 1989 Foi estudado o perfil isoenzimático da cepa Y do Trypanosoma cruzi isolada de camundongos tratados e não curados com o Nufurtimox (Bay 2502) ou com o Benzonidazol (Ro 7.1051), submetida à passagens em camundongos recém-nascidos e a seguir inoculada nos ...
Rosângela Castro Silva +3 more
doaj +1 more source
Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. [PDF]
, 2008 OBJECTIVE: To compare the cost-effectiveness of eflornithine and melarsoprol in the treatment of human African trypanosomiasis. METHOD: We used data from a Médecins Sans Frontières treatment project in Caxito, Angola to do a formal cost-effectiveness ...
Adam +23 more
core +2 more sources
Biological Research, 2004 Proteins rich in sulfhydryl groups, such as metallothionein, are present in several strains of the parasite Trypanosoma cruzi, the etiological agent of Chagas' disease.
JUAN DIEGO MAYA +7 more
doaj
Chagas Disease: “The Kiss of Death” [PDF]
, 2015 Chagas disease is a vector transmitted disease also known as American trypanosomiasis. Chagas disease is classified as a protist or protozoa, which is a simplified version of ‘animal-like single celled organism that is like a multicellular organism ...
Castro, Stacy, Rogers, Jessica
core +1 more source